Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction

Journal of the American Heart Association

Volumn 5, Issue 1, 2016, Pages

  Wang, Tracy Y ^a   Vora, Amit N ^a   Peng, S Andrew ^a   Fonarow, Gregg C ^b   Das, Sandeep ^c   de Lemos, James A ^c   Peterson, Eric D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Aldosterone antagonist therapy; Heart failure; Mortality; Older population

Indexed keywords

ALDOSTERONE ANTAGONIST; CREATININE; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; AGED; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPERKALEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; POST DISCHARGE MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; AGE; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; DRUG UTILIZATION REVIEW; FACTUAL DATABASE; HEART FAILURE; HEART STROKE VOLUME; MEDICARE; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; REGISTER; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGE FACTORS; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; HEART FAILURE; HUMANS; HYPERKALEMIA; MALE; MEDICARE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SPIRONOLACTONE; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84997840819     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002612     Document Type: Article

References (17)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Philippides GJ, Jacobs AK, Halperin JL, Albert NM, Creager MA, DeMets D, Guyton RA, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61: e179-e347.
2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78-e140.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
4. Hammill BG, Hernandez AF, Peterson ED, Fonarow GC, Schulman KA, Curtis LH. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J. 2009;157:995-1000.
5. Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, Barreto-Filho JA, Kim N, Bernheim SM, Suter LG, Drye EE, Krumholz HM. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309:355-363.
6. Jarrett N, Lux L, West S. Systematic evaluation of health outcome of interest definitions in observational studies and clinical definitions for the observational medical outcomes partnership: acute renal failure. Report prepared for the Foundation for the National Institutes of Health via the Observational Medical Outcomes Partnership (OMOP). Research Triangle Park, NC: RTI International; 2009.
7. Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA. 2013;309:241-242.
8. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1998;16:1141-1154.
9. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75:45-49.
10. Goyal A, de Lemos J, Peng SA, Thomas L, Amsterdam E, Hockenberry J, Peterson E, Wang T. The association of patient enrollment in Medicare Part D with outcomes after acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2015;8:567-575.
11. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013;61:35-40.
12. Rao KK, Enriquez JR, de Lemos JA, Alexander KP, Chen AY, McGuire DK, Fonarow GC, Das SR. Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG). Am Heart J. 2013;166:709-715.
13. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R; EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118:1643-1650.
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
15. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-551.
16. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
17. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845-849.